Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Stadler

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small, Susan Halabi, Mark J Ratain, et al.
Urology|February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancerCora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2010
Portable filter-based microdevice for detection and characterization of circulating tumor cellsHenry K Lin, Siyang Zheng, Anthony J Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Cancer|October 16, 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles, James E Herndon, Eric J Small, et al.
Cancer Research|October 3, 2003
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinomaNatalie C Twine, Jennifer A Stover, Bonnie Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Molecules (Basel, Switzerland)|August 26, 2023
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel TheranosticsJason P Meier, Hannah J Zhang, Richard Freifelder, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Cancer Research|July 5, 2005
A molecular classification of papillary renal cell carcinomaXiming J Yang, Min-Han Tan, Hyung L Kim, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small, Susan Halabi, Mark J Ratain, et al.
Urology|February 7, 2007
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancerCora N Sternberg, S Machele Donat, Joaquim Bellmunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2010
Portable filter-based microdevice for detection and characterization of circulating tumor cellsHenry K Lin, Siyang Zheng, Anthony J Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Cancer|October 16, 2004
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480Tim A Ahles, James E Herndon, Eric J Small, et al.
Cancer Research|October 3, 2003
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinomaNatalie C Twine, Jennifer A Stover, Bonnie Marshall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Molecules (Basel, Switzerland)|August 26, 2023
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel TheranosticsJason P Meier, Hannah J Zhang, Richard Freifelder, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Cancer Research|July 5, 2005
A molecular classification of papillary renal cell carcinomaXiming J Yang, Min-Han Tan, Hyung L Kim, et al.
Pageof 4